Catalog No.
DHD80802
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SAR-650984, hu38SB19, CAS: 1461640-62-9
Clone ID
Isatuximab
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, PMID: 31735560
Isatuximab for the treatment of relapsed/refractory multiple myeloma, PMID: 33111607
Isatuximab: First Approval, PMID: 32347476
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design, PMID: 31833394
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab, PMID: 31779273
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma, PMID: 30692097
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells, PMID: 32922390
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study, PMID: 32975869
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma, PMID: 30862646
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis, PMID: 32444867
Isatuximab, PMID: 32697463
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design, PMID: 29268619
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis, PMID: 32586908
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma, PMID: 33080623
Antibodies to watch in 2020, PMID: 31847708
Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date, PMID: 32446599
Correction to: Isatuximab: First Approval, PMID: 32447610
Incorporating isatuximab in the treatment of multiple myeloma, PMID: 31735559
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma, PMID: 30926770
Isatuximab: A Review of Its Use in Multiple Myeloma, PMID: 34351561
Immune-based therapies in the management of multiple myeloma, PMID: 32829378
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients, PMID: 33021075
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, PMID: 30858549
CD38 antibodies in multiple myeloma: back to the future, PMID: 29118010
Emerging agents and regimens for multiple myeloma, PMID: 33168044
Antibodies to watch in 2019, PMID: 30516432
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond, PMID: 29257139
Dexamethasone as a partner of isatuximab, PMID: 33661291
Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma, PMID: 32331242
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma, PMID: 32054831
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma, PMID: 28249894
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance, PMID: 30294326
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond, PMID: 26864107
Immunomodulatory effects of CD38-targeting antibodies, PMID: 29702148
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma, PMID: 32961764
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma, PMID: 32409691
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma, PMID: 28483761
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, PMID: 34097854
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis, PMID: 33839618
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018, PMID: 31076371
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab, PMID: 31409922
Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia, PMID: 34376579
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma, PMID: 34213061
Tafasitamab, PMID: 33355731
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma, PMID: 34185964
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies, PMID: 30498492
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis, PMID: 33432438
Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma, PMID: 34024861
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide, PMID: 26338273
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis, PMID: 34383345
For research use only. Not for human or drug use.
